오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - calcium chloride dihydrate, quantity: 270 mg/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - moxifloxacin hydrochloride, quantity: 1.74 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - moxifloxacin-baxter is indicated for treatment of adults who require initial i.v. therapy for the treatment of infections in the conditions: ? community acquired pneumonia (caused by susceptible organisms) ? acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics moxifloxacin-baxter is indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin-baxter may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - rocuronium bromide, quantity: 100 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; glacial acetic acid; sodium hydroxide; water for injections - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - rocuronium bromide, quantity: 50 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; glacial acetic acid; sodium hydroxide; water for injections - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.98 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium chloride; citric acid monohydrate; water for injections - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. prevention and treatment of post-operative nausea and vomiting.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 25 g/l; sodium chloride, quantity: 5.38 g/l; sodium lactate, quantity: 4.48 g/l; calcium chloride dihydrate, quantity: 183 mg/l; magnesium chloride hexahydrate, quantity: 50.8 mg/l - solution, irrigation - excipient ingredients: hydrochloric acid; water for injections - dianeal low calcium peritoneal dialysis solution is indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis or intermittent peritoneal dialysis and/or automated peritoneal dialysis and can also be used for acute renal failure.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 42.5 g/l; sodium chloride, quantity: 5.38 g/l; sodium lactate, quantity: 4.48 g/l; calcium chloride dihydrate, quantity: 183 mg/l; magnesium chloride hexahydrate, quantity: 50.8 mg/l - solution, irrigation - excipient ingredients: hydrochloric acid; water for injections - dianeal low calcium peritoneal dialysis solution is indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis or intermittent peritoneal dialysis and/or automated peritoneal dialysis and can also be used for acute renal failure.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 15 g/l; sodium chloride, quantity: 5.38 g/l; sodium lactate, quantity: 4.48 g/l; calcium chloride dihydrate, quantity: 183 mg/l; magnesium chloride hexahydrate, quantity: 50.8 mg/l - solution, irrigation - excipient ingredients: hydrochloric acid; water for injections - dianeal low calcium peritoneal dialysis solution is indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis or intermittent peritoneal dialysis and/or automated peritoneal dialysis and can also be used for acute renal failure.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 4.25 g/l; sodium chloride, quantity: 5.38 g/l; sodium lactate, quantity: 4.48 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 50.8 mg/l - solution, irrigation - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - dianeal low calcium peritoneal dialysis solution is indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis or intermittent peritoneal dialysis and/or automated peritoneal dialysis and can also be used for acute renal failure.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose monohydrate, quantity: 25 g/l; sodium chloride, quantity: 5.38 g/l; sodium lactate, quantity: 4.48 g/l; calcium chloride dihydrate, quantity: 257 mg/l; magnesium chloride hexahydrate, quantity: 50.8 mg/l - solution, irrigation - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code),dianeal low calcium peritoneal dialysis solution is indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis or intermittent peritoneal dialysis and/or automated peritoneal dialysis and can also be used for acute renal failure.